Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Version 1 : Received: 27 December 2023 / Approved: 8 January 2024 / Online: 8 January 2024 (02:23:44 CET)

A peer-reviewed article of this Preprint also exists.

Mendoza-Salazar, I.; Fragozo, A.; González-Martínez, A.P.; Trejo-Martínez, I.; Arreola, R.; Pavón, L.; Almagro, J.C.; Vallejo-Castillo, L.; Aguilar-Alonso, F.A.; Pérez-Tapia, S.M. Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb). Pharmaceuticals 2024, 17, 185. Mendoza-Salazar, I.; Fragozo, A.; González-Martínez, A.P.; Trejo-Martínez, I.; Arreola, R.; Pavón, L.; Almagro, J.C.; Vallejo-Castillo, L.; Aguilar-Alonso, F.A.; Pérez-Tapia, S.M. Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb). Pharmaceuticals 2024, 17, 185.

Abstract

Monomeric Ubiquitin (Ub) is a 76-amino acid highly conserved protein found in eukaryotes. The first described biological activity of Ub in the 1970s was extracellular, but it quickly gained relevance due to its intracellular role, i.e., post-translational modification of intracellular proteins (ubiquitination) that regulate numerous eukaryotic cellular processes. In the following years, the extracellular role of Ub was relegated to the background, until a correlation between higher survival rate and increased serum Ub concentrations in patients with sepsis and burns was observed. Although the mechanism of action (MoA) of extracellular ubiquitin (eUb) is not yet well understood, further studies have shown that it may ameliorate the inflammatory response in tissue injury and multiple sclerosis diseases. These observations compounded with the high stability and low immunogenicity of eUb due to its high conservation in eukaryotes have made this small protein a relevant candidate for biotherapeutic development. Here, we review the in vitro and in vivo effects of eUb on immunologic, cardiovascular, and nervous systems, and discuss the potential MoAs of eUb as an anti-inflammatory, antimicrobial, cardio- and brain-protective agent.

Keywords

Extracellular ubiquitin; monomeric ubiquitin; immunomodulatory drugs; sepsis; biotherapeutic proteins

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.